New Syngene Platform Aims for Rapid Protein Production

Editor's note: this story was originally published on BioPharmInternational.com.

A new production platform from Syngene International, a contract research, development, and manufacturing organization (CRDMO), offers rapid protein synthesis using a cell line and transposon-based technology that Syngene licensed from ExcellGene, a Switzerland-based service provider specializing in mammalian cell line development. ExcellGene's technology combined with Syngene’s clone selection and development processes means that the new platform provides a significant improvement in efficiency and precision, according to Syngene in a June 4, 2024 company press release.

With enhanced protein production, the platform offers faster preclinical and clinical development and shorter timelines to product launches, reducing the time to market. The platform’s advantages include:

• Up to 10 weeks reduction in time versus traditional cell line development methods

• Better predictability and protein yields, with high-titer levels of up to 10 g/L achieved
• Monoclonal antibodies, biosimilars, bispecific antibodies, antibody drug conjugates, and other recombinant proteins are all supported on the platform.

"By combining the cell line and transposon-based platform from ExcellGene with our proprietary processes, we are pushing the boundaries in cell line development. This innovative approach will not only accelerate development timelines but also enhance the overall reliability and efficiency of the process, delivering substantial benefits to our clients," said Sridevi Khambhampaty, vice-president, Biopharmaceutical Development, Syngene International, in the press release.

"Syngene sees biologics as a key driver of future growth, and we are committed to investing in cutting-edge technology to achieve reliability, precision, and speed for clients. By combining Syngene’s skills and experience with ExcellGene’s best-in-class cell line development technology, we can expedite getting molecules to market for the people and patients who need them," added Alex Del Priore, senior vice-president, Manufacturing Services, Syngene International, in the release.

According to Syngene, the versatility of the platform facilitates integration with perfusion and fed-batch manufacturing processes. “By combining this technology with Syngene’s existing capabilities, the [c]ompany now offers a full range of end-to-end cell line development options, using the latest technology to deliver tangible benefits to customers,” the company stated in its release.

“High yield manufacturing is a multifactorial exercise that starts with transfections and an optimized cell host. We are obviously delighted to partner with and to contribute to Syngene’s process development and manufacturing capabilities. This will leverage our technology and our cells (CHOExpress) for the benefit of their extensive client base. At ExcellGene, we pride ourselves in having studied the profound challenges in DNA transfer to cultivated cells for decades and linked insights from such studies to their phenotypes and use in manufacturing. We are delighted that our work, combined with the talent and expertise of the Syngene team, will directly benefit patients around the world,” said Maria J. and Florian M. Wurm, co-founders and managers, ExcellGene, in the release.

Source: Syngene International